Racial disparities in lung transplantation for cystic fibrosis in the era of highly effective modulator therapy
Journal of Cystic Fibrosis · 2025
DOI: 10.1016/j.jcf.2025.01.006 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Cystic Fibrosis, 2025. Verfasst von Jessica M Ruck und 9 weiteren Autor:innen. Beteiligte Einrichtung: Division of Thoracic Surgery, Department of Surgery, Johns Hopkins University School of Medicine, Baltimore, MD, USA. Hauptthemen laut MEDLINE: Cystic Fibrosis, Lung Transplantation, Healthcare Disparities. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 25 Literaturangaben. Gefördert von: NIA NIH HHS, NIDDK NIH HHS, U.S. Department of Health and Human Services.
Abstract (Originalsprache)
BACKGROUND: Highly effective modulator therapies (HEMT) including ivacaftor (IVA) and elexacaftor/tezacaftor/ivacaftor (ETI) have transformed treatment for people with cystic fibrosis (pwCF). However, non-HEMT-responsive mutations are more common in pwCF of non-White race/ethnicity; introduction of HEMT might have exacerbated racial/ethnic disparities in CF care. METHODS: Using the Scientific Registry of Transplant Recipients, we identified all lung transplant candidates and recipients 05/2005-12/2022 and categorized them by diagnosis (CF/non-CF), race/ethnicity (non-Hispanic White/Black/Hispanic) and era [Pre-HEMT (2005-1/30/2012), IVA (1/31/2012-10/30/2019), ETI (10/31/2019-12/31/2022)]. We compared the percentage of patients listed, delisted/died, or transplanted by race/ethnicity and era. RESULTS: 34,659 lung transplants were performed: 10,521 pre-HEMT, 15,944 in IVA era, and 7,888 in ETI era. Over the three eras, the percentage of lung recipients with CF of White race decreased (94.5 % to 92.4 % to 78.4 %) and of Black race (1.7 % to 2.4 % to 5.7 %) or Hispanic ethnicity increased (3.5 % to 4.6 % to 14.2 %; p < 0.001). Similarly, among candidates listed for CF over the three eras, the percentage that were of White race decreased (82.0 % vs. 78.6 % vs. 71.0 %) and of Black race (9.2 % vs. 10.0 % vs. 10.3 %) or Hispanic ethnicity increased (6.4 % vs. 8.6 % vs. 13.6 %; p < 0.001). CONCLUSION: The introduction of HEMT appears to have benefitted CF lung transplant candidates and recipients of Black race or Hispanic ethnicity less than those of White race. This is likely due to the higher prevalence of HEMT-ineligible CFTR mutations among Black and Hispanic patients and underscores the need for therapies aimed at non-HEMT-responsive mutations prevalent in these racial/ethnic populations.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Thoracic Surgery, Department of Surgery, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
- Division of Pulmonology and Critical Care Medicine, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
- Director, Advanced Lung Disease Program, Cystic Fibrosis Foundation, Bethesda, MD, USA.
- Division of Pulmonology and Critical Care Medicine, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA; Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, B…
- Department of Surgery, New York University Grossman School of Medicine and Langone Health, New York, NY, USA; Department of Population Health, New York University Grossman School of Medicine and Langone Health, New York…
Förderung
- NIA NIH HHS
- NIDDK NIH HHS
- U.S. Department of Health and Human Services
- National Institute of Diabetes and Digestive and Kidney Diseases
- National Institute on Aging
- Hennepin Healthcare Research Institute
Zitieren
APA
Ruck, J. M., Feng, S. N., Toporek, A. H., Shah, P. D., Tallarico, E., Lechtzin, N., Massie, A. B., Segev, D. L., Bush, E. L., & Merlo, C. A. (2025). Racial disparities in lung transplantation for cystic fibrosis in the era of highly effective modulator therapy. Journal of Cystic Fibrosis. https://doi.org/10.1016/j.jcf.2025.01.006
Vancouver
Ruck JM, Feng SN, Toporek AH, Shah PD, Tallarico E, Lechtzin N, et al. Racial disparities in lung transplantation for cystic fibrosis in the era of highly effective modulator therapy. Journal of Cystic Fibrosis. 2025. doi:10.1016/j.jcf.2025.01.006
BibTeX
@article{Ruck2025,
author = {Ruck, Jessica M and Feng, Shi Nan and Toporek, Alexandra H and Shah, Pali D and Tallarico, Erin and Lechtzin, Noah and Massie, Allan B and Segev, Dorry L and Bush, Errol L and Merlo, Christian A},
title = {Racial disparities in lung transplantation for cystic fibrosis in the era of highly effective modulator therapy},
journal = {Journal of Cystic Fibrosis},
year = {2025},
doi = {10.1016/j.jcf.2025.01.006}
}
EUVIMED